ChiCTR2500105214 版本V1.0 版本创建时间2025/06/30 22:16:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500105214 

最近更新日期:

Date of Last Refreshed on:

2025-06-30 22:15:55 

注册时间:

Date of Registration:

2025-06-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于无线可穿戴设备的6分钟步行试验系统在肺癌手术患者中的应用

Public title:

Application of 6-minute walking test system based on wireless wearable devices in patients with lung cancer surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于无线可穿戴设备的6分钟步行试验系统在肺癌手术患者中的应用

Scientific title:

Application of 6-minute walking test system based on wireless wearable devices in patients with lung cancer surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

廖虎 

研究负责人:

廖虎 

Applicant:

Hu Liao 

Study leader:

Hu Liao 

申请注册联系人电话:

Applicant telephone:

+86 189 8060 5130

研究负责人电话:

Study leader's telephone:

+86 189 8060 5130

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liaotiger_198653@163.com

研究负责人电子邮件:

Study leader's E-mail:

drliaohu@scu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital of Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年审(1647)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Ethics Committee on Biomedical Research West China Hospital of Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-04 00:00:00

伦理委员会联系人:

李娜

Contact Name of the ethic committee:

Lina

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 2654

伦理委员会联系人邮箱:

Contact email of the ethic committee:

188974152@qq.com

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-raised

Target disease:

Lung cancer patients over 18 years old undergoing pneumonectomy

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1. 主要目的:探究基于无线可穿戴设备测量的行肺癌切除术患者围术期6分钟步行试验结果与其围术期结局的关联。 2. 次要目的:探究基于无线可穿戴设备在行肺癌切除术患者围术期常规开展6分钟步行试验的安全性及可行性。  

Objectives of Study:

1. main objective: To explore the correlation between the results of the 6-minute walk test and the perioperative outcome of patients undergoing lung cancer resection based on the measurement of wireless wearable devices. 2. secondary objective: To explore the safety and feasibility of 6-minute walk test based on wireless wearable devices in patients undergoing lung cancer resection.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄:(1)≥18岁 2. 手术:(1)计划行胸腔镜下肺切除术(肺叶、肺段切除) (2)美国麻醉医师协会(ASA)风险等级I-II级 3. 诊断:(1)术后病理确诊为肺癌 4. 知情同意:(1)理解操作流程并能正常沟通 (2)签署知情同意;

Inclusion criteria

1. Age: (1) >= 18 years old 2. Surgery: (1) thoracoscopic pneumonectomy (lobectomy and segmentectomy) is planned (2) American Society of anesthesiologists (ASA) risk level I-II 3. Diagnosis: (1) postoperative pathological diagnosis of lung cancer 4. Informed consent: (1) understand the operation process and communicate normally (2) Sign informed consent;

排除标准:

1.监护设备:(1)有植入式心脏装置 (2)对贴附点击材料过敏 (3)贴附部位周围有伤口或皮肤损伤 2.健康状况:(1)严重或不稳定的精神疾病(重度抑郁或精神分裂等) (2)严重或不稳定的躯体疾病(心脏衰竭、肝脏衰竭、脑卒中等) (3)妊娠或哺乳期妇女(18-55岁都要做尿妊娠试验) 3.手术:(1)楔形切除 (2)术中大出血(>500ml);

Exclusion criteria:

1. The monitoring device: (1) has an implantable heart device (2) Allergic to attached click materials (3) Wound or skin damage around the attachment site 2. Health status: (1) severe or unstable mental illness (severe depression or schizophrenia, etc.) (2) Severe or unstable physical diseases (heart failure, liver failure, stroke, etc.) (3) Pregnant or lactating women (urine pregnancy test is required for 18-55 years old) 3. Operation: (1) wedge resection (2) Intraoperative massive hemorrhage (>500ml);

研究实施时间:

Study execute time:

From 2024-08-01 00:00:00 To 2027-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-30 00:00:00 To 2027-07-31 00:00:00  

干预措施:

Interventions:

组别:

六分钟步行试验组

样本量:

320

Group:

Six minute walk test group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

四川省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Sichuan Provincial People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

四川省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Sichuan Cancer Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

成都上锦南府医院 

单位级别:

三级甲等 

Institution
hospital:

Chengdu Shang Jin Nan Fu Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

成都市第三人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Third People's Hospital of Chengdu

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

成都市公共卫生临床医疗中心 

单位级别:

三级甲等 

Institution
hospital:

Public Health Clinical Center of Chengdu

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

四川大学华西第四医院 

单位级别:

三级甲等 

Institution
hospital:

West China Fourth Hospital of Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

 

单位(医院):

四川大学华西天府医院 

单位级别:

三级甲等 

Institution
hospital:

West China Tianfu Hospital, Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

可穿戴设备的6分钟步行测试的结果(距离和氧饱和度、呼吸频率、心率、心电、血压等)与术后并发症之间的关系

指标类型:

主要指标

Outcome:

Relationship between the results of 6-minute walk test of wearable devices (distance and oxygen saturation, respiratory rate, heart rate, ECG, blood pressure, etc.) and postoperative complications

Type:

Primary indicator

测量时间点:

住院期间

测量方法:

基于可穿戴设备的6分钟步行测试的结果(距离和氧饱和度、呼吸频率、心率、心电、血压等)与术后并发症之间的关系。术后并发症包括:气胸、咯血、支气管胸膜瘘、持续漏气、胸腔积液、肺炎、急性呼吸窘迫综合征等。

Measure time point of outcome:

During hospitalization

Measure method:

The relationship between the results of 6-minute walk test (distance and oxygen saturation, respiratory rate, heart rate, ECG, blood pressure, etc.) based on wearable devices and postoperative complications. Postoperative complications include pneumothorax, hemoptysis, bronchopleural fistula, persistent air leakage, pleural effusion, pneumonia, acute respiratory distress syndrome, etc.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2028年01月01日共享原始数据,通过学术文章形式发布

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

January 1, 2028 share the original data and publish it in the form of academic articles

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

统计分析计划书由统计人员撰写,在数据库锁定前定稿,以多种表格组成。主要分析内容有组间的有效性差异和安全性差异等。所有主要研究指标和次要研究指标分析采用意向治疗分析法(intention-to-treat analysis, ITT)。所有计量资料的描述性分析采用均数、标准差、中位数、四分位数间距、最大值和最小值指标,其正态性检验使用Shapiro-Wilk test。所有计数资料的描述性分析用率、构成比等指标;统计推断根据统计方法的适用条件选择合适的假设检验方法,包括Student’s t test,Mann-Whitney U test,χ2 test等;。需对各组不同数据集、病例分布、总脱落病例、终止原因详细列表等进行分析,其中脱落病例所占的比例不宜超过20%,否则应加以分析说明。所有缺失数据不填补。所有分析采用双侧检验,计算假设检验的P值和95%置信区间,P<0.05将被认为组间的差别有统计学意义。所有统计学分析采用SPSS 15.0及R 4.3.3进行

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The statistical analysis plan is written by statisticians and finalized before the database is locked. It is composed of a variety of tables. The main analysis contents include the effectiveness differences and safety differences between groups. Intention to treat analysis (ITT) was used to analyze all primary and secondary research indicators. The descriptive analysis of all measurement data uses the mean, standard deviation, median, interquartile distance, maximum and minimum indicators, and its normality test uses Shapiro - Wilk test. The descriptive analysis rate, constituent ratio and other indicators of all count data; Statistical inference selects appropriate hypothesis testing methods according to the applicable conditions of statistical methods, including student's t test, Mann Whitney U test, χ 2 test, etc;. It is necessary to analyze the different data sets, case distribution, total dropped cases and detailed list of termination reasons in each group. The proportion of dropped cases should not exceed 20%, otherwise it should be analyzed and explained. All missing data will not be filled. Two sided test was used in all analyses. The p value and 95% confidence interval of hypothesis test were calculated. P<0.05 would be considered as the difference between groups with statistical significance. All statistical analyses were performed using SPSS 15.0 and R 4.3.3

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-06-30 22:15:55